… Investor/Analyst Webcast: Lilly Partnership Expansion and Axiomer Overview ProQR Management will host an investor … conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the … 30 days following the presentation date. About Axiomer ® ProQR is pioneering a next-generation RNA base …
Find all relevant presentations and publications for each of our programs. From review papers to preclinical posters and clinical data presentations at medical conferences.
… ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration … directed to up to five targets u sing ProQR’s proprietary Axiomer ® RNA editing platform ProQR to receive $ 5 0 million …
… ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio LEIDEN, Netherlands & CAMBRIDGE, Mass., … a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition was filed in June 2021 with the …
… ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration Partnership focused on … said Daniel A. de Boer, Chief Executive Officer of ProQR. “Axiomer has the potential to restore precise levels of the …
… ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 Platform … transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today highlighted …
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025
Axiomer activity demonstrated across multiple preclinical in vitro
